Letrozol STADA® 2
Sponsors
F. Hoffmann-La Roche AG, Verastem Inc.
Conditions
Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-MutatedEstrogen Receptor-PositiveHER2-Negative Early Breast CancerHormone Receptor-PositiveMetastatic breast cancerRecurrent Low-Grade Serous Ovarian Cancer (LGSOC)and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)hormone receptor positive breast cancer (HR+ BC)
Phase 1
Phase 3
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP301)
RecruitingCTIS2023-508204-38-00
Start: 2024-07-02Target: 183Updated: 2026-01-06
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer
Active, not recruitingCTIS2023-507172-44-00
Start: 2021-09-10Target: 1482Updated: 2025-11-25
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients with Endocrine-Sensitive PIK3CA -Mutated, Hormone Receptor-Positive, HER2- Negative Advanced Breast Cancer
RecruitingCTIS2024-516162-11-00
Start: 2025-07-14Target: 176Updated: 2025-11-10